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Purpose: To report a patient erroneously diagnosed with tuberculous choroiditis 
who was accordingly treated with long term steroids which in turn, worsened the 
actual disease process that turned out to be central serous chorioretinopathy (CSC).
Case Report: A 59-year-old Caucasian man developed a chorioretinal disease in his 
right eye in 1997. Having a positive tuberculin skin test, tuberculous chorioretinitis 
was suspected and antituberculous therapy was administered for 4 months. In 2005, 
visual symptoms in the same eye recurred and despite negative interferon gamma 
release assay, tuberculous choroiditis was considered as the diagnosis and the 
patient further received massive corticosteroid therapy along with antituberculous 
agents. Despite a deteriorating clinical picture, therapy was continued. Upon initial 
examination at our center, no sign of inflammation was observed and a diagnosis of 
CSC was made, consequently steroid therapy was terminated.
Conclusion: In some chorioretinopathies, it is difficult to differentiate inflammatory 
from non-inflammatory causes. One should observe the course of the disease and 
question the initial diagnosis when no improvement or deterioration occurs despite 
therapy.
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INTRODUCTION
Central serous chorioretinopathy (CSC) is 
a condition which may be exacerbated by 
corticosteroids in susceptible individuals.1 
When affected patients are referred to uveitis 
clinics, the condition runs the risk of being 
assimilated as an inflammatory condition. CSC 
is not completely understood; it has systemic 
associations, a multifactorial etiology and a 
complex pathogenesis. Increased permeability 
of choroidal vessels is thought to cause focal 
or diffuse leakage under the retinal pigment 
epithelium (RPE) resulting in
neurosensory retinal dysfunction. Detach-
ments of the neurosensory retina are usually 
associated with multiple small or large RPE 
detachments which are quasi diagnostic when 
present.2
In the case of certain chorioretinopathies, 
distinguishing inflammatory from non-
inflammatory causes is rather difficult. One 
of the entities that can mimic an inflammatory 
chorioretinopathy is CSC or its more aggressive/
chronic form, diffuse retinal pigment 
epitheliopathy.CSC Mistaken for Tuberculous Choroiditis; Papadia and Herbort
335 JOURNAL OF OPHTHALMIC AND VISION RESEARCH 2011; Vol. 6, No. 4
It is critical to identify CSC or its chronic 
form in patients referred to uveitis centers 
otherwise, there is a real danger that the 
patient be treated with corticosteroids which 
are likely to aggravate the disease and cause 
irreversible damage.
Development of CSC following administra-
tion of corticosteroids by a variety of routes 
is a well-known phenomenon.3 Herein, 
we report acute visual loss after receiving 
systemic corticosteroids in a patient whose 
CSC was initially misinterpreted as tuberculous 
choroiditis and was treated with antituberculous 
chemotherapy combined with systemic 
corticosteroids despite repeated negative 
interferon gamma releasing assays (IGRAs), 
leading to progressive worsening of the 
condition over a ten-year period.
CASE REPORT
A 59-year-old Caucasian man was diagnosed 
with a non-specified chorioretinal disorder 
in his right eye back in 1997; at that time he 
received antituberculous chemotherapy for 4 
months due to a positive tuberculin skin test 
(12 by 16 mm induration). A recrudescence of 
psoriasis, which the patient used to treat with 
corticosteroid ointments, had preceded the ocular 
symptoms. In 2005, after another exacerbation 
of psoriasis, visual symptoms recurred in 
the same eye. Uveitis work-up showed only 
a positive tuberculin skin test considering 
the fact that he had received BCG (Bacillus 
Calmette-Guerin) vaccination. Tuberculous 
chorioretinitis was suspected once more and 
antituberculous quadri-therapy together with 
systemic corticosteroids was initiated despite 
a negative IGRA test (QuantiFERON-TB Gold 
In-Tube, Cellestis, Carnegie, Australia). This 
test identifies latent or active tuberculous 
infection by detecting memory T-cells reacting 
against Mycobacterium tuberculosis proteins. It 
measures the release of interferon gamma in 
response to antigens of this certain type of 
bacterium but not to the BCG vaccine nor to 
most non-tuberculous mycobacteria. Despite 
this therapy, visual acuity worsened.
In 2010, when the patient attended our 
center for a second opinion, he was still 
on low-dose systemic corticosteroids. Best 
corrected visual acuity (BCVA) was 0.05 and 
1.0 in the right and left eyes respectively. Both 
anterior segments were normal and laser flare 
photometry (Kowa FM-500, Kowa Ltd., Tokyo, 
Japan) measured slight subclinical disruption 
of the blood-aqueous barrier in both eyes 
(9.7 and 9.4 ph/ms in the right and left eyes 
respectively). Intraocular pressure was 14 
mmHg in both eyes. On fundus examination, 
rare pigmented cells were found in the vitreous 
body of the right eye, along with widespread 
chorioretinal scars in both eyes.
Visual field testing (G1 program of 
the Octopus 900, G Standard; Haag-Streit 
International, Bern, Switzerland) demonstrated 
severe loss of the superior visual field in the 
right eye and an absolute superior scotoma in 
the left eye; both field defects corresponded 
to chorioretinal lesions visible on fundus 
examination (Fig. 1).
OCT (OTI Spectral OCT/SLO; Ophthalmic 
Technologies Inc., Toronto, Canada) scan 
showed a large serous RPE detachment adjacent 
to a smaller one in the right eye, and a minute 
serous RPE detachment in the left eye (Fig. 2).
On fluorescein angiography (FA) 
hyperfluorescent areas were seen, indicating 
exudation and atrophy corresponding to the 
Figure 1. Visual field testing shows severe loss of the 
superior visual field in the right eye (upper image) and 
an absolute scotoma in the left one (lower image).CSC Mistaken for Tuberculous Choroiditis; Papadia and Herbort
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chorioretinal lesions observed on fundus 
examination, while no signs of inflammation 
or vasculitis were present (Fig. 3).
Indocyanine green angiography (ICGA) 
revealed a round dark area, corresponding to 
the large exudative right RPE detachment and 
also late diffuse choroidal hyperfluorescence 
in both eyes as can usually be found in 
patients with CSC. The dark area was caused 
by capillary closure due to pressure exerted 
by the RPE detachment, or by masking effect 
because of increased liquid density in the RPE 
detachment (Fig. 4).
Based on these findings, a diagnosis of 
CSC was made and corticosteroid therapy was 
discontinued. Earlier ICGA and FA images 
(when the disease had first appeared in 1997) 
were requested from the center that had taken 
care of the patient. FA showed no signs of 
inflammation, while ICGA frames showed areas 
of diffuse late choroidal hyperfluorescence, a 
finding typical for CSC (Fig. 5).
After 6 months, OCT, FA and ICGA 
remained unchanged as did visual acuity. 
Visual field improvement was the only sign, 
if any, of recovery.
DISCUSSION
The deleterious effects of corticosteroids in 
terms of predisposing to or aggravating CSC 
are widely recognized.4 This issue should be 
borne in mind when unexpected clinical and 
angiographic evolution compatible with CSC 
occurs in a putative uveitis patient treated with 
corticosteroids.
The long-term visual prognosis of CSC 
is fair without treatment, but a significant 
Figure 3. Fluorescein angiography demonstrates 
hyperfluorescent areas corresponding to exudation 
and/or chorioretinal scars without any sign of vasculitis 
or inflammation.
Figure 4. ICGA shows a round dark area corresponding 
to the right RPE detachment and late diffuse posterior 
pole hyperfluorescence.
Figure 5. FA and ICGA frames reclaimed from the 
former treatment center. FA (bottom frames) shows 
no signs of an inflammatory condition whereas, ICGA 
(top eight frames) shows signs clearly compatible 
with CSC, especially bilateral late diffuse choroidal 
hyperfluorescence.
Figure 2.  OCT images show a large RPE detachment 
adjacent to a smaller one together with intraretinal 
edema in the right eye (top image), and a very small 
serous RPE detachment in the left eye (bottom image).CSC Mistaken for Tuberculous Choroiditis; Papadia and Herbort
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proportion of patients develop recurrences.5 FA 
and ICGA, along with OCT scans are essential 
tools in the diagnosis of both inflammatory eye 
diseases and CSC.6
Foveal attenuation, chronic macular edema, 
and damage to the photoreceptor layer have 
been reported as causes of visual loss in CSC. 
Photoreceptor atrophy in the fovea, despite 
successful retinal reattachment, typically occurs 
when the duration of symptoms exceeds 4 
months.7
It should be mentioned that although 
the incidence of tuberculous choroiditis has 
increased in the past decades, its diagnosis 
should be supported by a positive IGRA test.8 
This seems to have been one of the major pitfalls 
in the management of this patient.
The possibility of CSC development in 
uveitis patients should be kept in mind as an 
adverse effect of corticosteroid therapy and 
should not be mistaken as worsening of uveitis 
resulting in an erroneous increase in intensity 
of steroid therapy.3
The case described herein demonstrates 
how an incorrect inflammatory diagnosis made 
at the beginning and later, was never doubted 
during follow-up visits leading to irreversible 
retinal damage caused by aggravation of CSC 
due to corticosteroids.
Conflicts of Interest
None.
REFERENCES
1.  Abu el-Asrar AM. Central serous chorioretinopathy 
complicating systemic corticosteroid therapy. Eur J 
Ophthalmol 1997;7:297-300.
2.  Gemenetzi M, De Salvo G, Lotery AJ. Central serous 
chorioretinopathy: an update on pathogenesis and 
treatment. Eye (Lond) 2010;24:1743-1756.
3.  Schalenbourg A, Leys A, De Courten C, Coutteel 
C, Herbort CP. Corticosteroid-induced central 
serous chorioretinopathy in patients with ocular 
inflammatory disorders. Klin Monbl Augenheilkd 
2002;219:264-267.
4.  De Nijs E, Brabant P, De Laey JJ. The adverse 
effects of corticosteroids in central serous 
chorioretinopathy. Bull Soc Belge Ophtalmol 
2003;289:35-41.
5.  Fok AC, Chan PP, Lam DS, Lai TY. Risk factors 
for recurrence of serous macular detachment 
in untreated patients with central serous 
chorioretinopathy. Ophthalmic Res 2011;46:160-163.
6.  Bandello F, Virgili G, Lanzetta P, Pirracchio 
A, Menchini U. ICG angiography and retinal 
pigment epithelial decompensation (CRSC and 
epitheliopathy). J Fr Ophtalmol 2001;24:448-451.
7.  Wang MS, Sander B, Larsen M. Retinal atrophy in 
idiopathic central serous chorioretinopathy. Am J 
Ophthalmol 2002;133:787-793.
8.  Cimino L, Herbort CP, Aldigeri R, Salvarani C, 
Boiardi L. Tuberculous uveitis, a resurgent and 
underdiagnosed disease. Int Ophthalmol 2009;29:67-
74.